We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mylan Confirms First-to-File Patent Challenge Relating to Zytiga
News

Mylan Confirms First-to-File Patent Challenge Relating to Zytiga

Mylan Confirms First-to-File Patent Challenge Relating to Zytiga
News

Mylan Confirms First-to-File Patent Challenge Relating to Zytiga

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mylan Confirms First-to-File Patent Challenge Relating to Zytiga"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This product is the generic version of Zytiga®, which is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. 

Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity upon final FDA approval. The plaintiffs have filed a lawsuit against Mylan in the United States District Court for the District of New Jersey.

For the 12 months ending June 30, 2015, Zytiga had U.S. sales of approximately $1.08 billion, according to IMS Health.

Currently, Mylan has 268 ANDAs pending FDA approval representing $101.3 billion in annual brand sales, according to IMS Health. Fifty of these pending ANDAs are potential first-to-file opportunities, representing $33.4 billion in annual brand sales, for the 12 months ending December 31, 2014, according to IMS Health.

Advertisement